Lecanemab for people with Parkinson's disease who also have Alzheimer's-type amyloid in the brain
Tests lecanemab in people with Parkinson's disease and amyloid buildup in the brain.
Key facts
- Who runs it
- Yonsei University
- Where
- Seoul, South KoreaSee the site
- Trial code
- Registry title
- Amyloid Monoclonal Antibody Treatment in PD Patients With Coexistent AD Pathology
- Status
- Not yet recruiting
- People taking part
- 60 people, planned
- Started
- May 2026
- Expected to end
- Nov 2030
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Lecanemab
- Lecanemab non-administration group
- Record updated
- 22 April 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with Parkinson's disease who also have amyloid in the brain and mild memory or thinking problems or early dementia.
- Age
- 50 to 90 years
- Sex
- All sexes
- Disease stage
- Parkinson's disease with mild cognitive impairment or early dementia (CDR 0.5 or 1) on thinking tests.
- Biomarker or test result
- Amyloid deposits in the brain confirmed by FBB PET scan.
Main reasons for not taking part
- Lecanemab cannot be given safely (contraindicated)
- Another brain disease besides Parkinson's disease or Alzheimer's disease is suspected
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- Patients diagnosed with Parkinson's disease
- Amyloid deposition confirmed by FBB PET
- Mild cognitive impairment or early dementia (CDR 0.5 or 1) on neuropsychological tests
- Adults aged 50-90 years
Who cannot take part
- Cases in which lecanemab administration is contraindicated (based on recommendations from the Korean Dementia Association)
- Cases in which neuropathologies other than Parkinson's disease or Alzheimer's disease are suspected as the underlying disease
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 50 and 90 years old?
Where in South Korea
- Yonsei University College of MedicineSeoul, South KoreaContact: Phil Hyu Lee, MDNot yet recruiting
About the trial
What the trial wants to find out
This study aimed to determine the efficacy of amyloid clearance of lecanemab in patients with Parkinson's disease (PD) with amyloid co-pathology. Lecanemab, an anti-amyloid monoclonal antibody, was apporoved by the US FDA in July 2023 and in South Korea in May 2024, as a disease-modifying therapy based on its clinical efficacy and reduction of amyloid plaques in patients with early-stage Alzheimer's disease (AD). AD pathology is also common in PD, and approximately 35% of patients with PD dementia have co-existing AD pathology. Currently, no mediations have been developed to slow the progression of PD. Therefore, this study aimed to determine whether reducing the amyloid burden in patients with PD with co-exsistent AD pathology could potentially slow disease progression. To test it, patients with PD with mild cognitive impairment or early dementia, who were confirmed to have amyloid deposition through amyloid imaging, would be enrolled as a treatment arm, and the degree of reduction of amyloid plaque after 18 months of lecanemab administration would be investigated.
The 2 groups in the trial
- Lecanemab admnistration groupTreatment being tested
Patients who receive lecanemab 10mg/kg every two weeks for 18 months
Treatment: Lecanemab
- Lecanemab non-admnistration groupExisting treatment, for comparison
Patients who do not receive lecanemab
Treatment: Lecanemab non-administration group
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Efficacy of Lecanemab in Patients With Parkinson's Disease With Coexistent Alzheimer's Disease
- Plain-language title
- Lecanemab for people with Parkinson's disease who also have Alzheimer's-type amyloid in the brainGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 13 November 2026.
- Fit questions
- Built from NCT07544953, who can take part
- Record updated
- 22 April 2026